SCHEMBL12420362

SCHEMBL12420362

COc1cccc(-c2noc(-c3ccccc3)n2)c1

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 13/20 0.88
RAB9A P51151 13/20 0.88
SMN1; SMN2 Q16637 8/20 0.88
TP53 P04637 7/20 0.88
NFKB1 P19838 3/20 0.88
NFKB2 Q00653 3/20 0.88
RELA Q04206 3/20 0.88
TDP1 Q9NUW8 2/20 0.88
MAPT P10636 8/20 0.75
MEN1 O00255 4/20 0.75
KMT2A Q03164 4/20 0.75
CYP1A2 P05177 1/20 0.72
CYP3A4 P08684 1/20 0.72
CYP2D6 P10635 1/20 0.72
CYP2C9 P11712 1/20 0.72
CYP2C19 P33261 1/20 0.72
NR1H4 Q96RI1 2/20 0.72
S1PR1 P21453 1/20 0.72
CA2 P00918 1/20 0.70
CA9 Q16790 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12692350 0.86 NPC1 (0.86) NPC1RAB9ASMN1; SMN2TP53NFKB1
SCHEMBL59673 0.85 NPC1 (0.73) NPC1RAB9ASMN1; SMN2TP53NFKB1
SCHEMBL1427471 0.85 NPC1 (0.73) NPC1RAB9ASMN1; SMN2TP53NFKB1
SCHEMBL6697420 0.84 NR1H4 (1.00) NPC1RAB9ASMN1; SMN2TP53NFKB1
SCHEMBL7291752 0.84 NR1H4 (1.00) NPC1RAB9ASMN1; SMN2TP53NFKB1
SCHEMBL4180934 0.83 NPC1 (0.81) NPC1RAB9ASMN1; SMN2TP53NFKB1
SCHEMBL17570197 0.83 NR1H4 (0.80) NPC1RAB9ASMN1; SMN2TP53NFKB1
SCHEMBL16067423 0.83 L3MBTL1 (0.72) NPC1RAB9ASMN1; SMN2TP53NFKB1
SCHEMBL26093743 0.82 RAB9A (0.79) NPC1RAB9ASMN1; SMN2TP53NFKB1
SCHEMBL12171366 0.82 NPC1 (0.78) NPC1RAB9ASMN1; SMN2TP53NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130096165-A1 COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS IRM LLC (BM) 2013-04-18 US disclosed
US-8362050-B2 Compounds and methods for modulating G protein-coupled receptors IRM LLC (BM) 2013-01-29 US disclosed
US-20110172278-A1 COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS IRM LLC (BM) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096165-A1 COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS GRK2, GRK3, GPR3 NPC1 856/4885RAB9A 1104/4885SMN1; SMN2 4686/4885
US-20110172278-A1 COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS GRK2, GRK3, GPR3 NPC1 856/4885RAB9A 1104/4885SMN1; SMN2 4686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.